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Synchronous tumors of the pancreas and the gallbladder: a case 
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Abstract: Synchronous tumors of the pancreas and gallbladder are rare and often attributed to an abnormal 
pancreato-biliary junction, which results in a persistent reflux of pancreatic secretions leading to chronic 
biliary inflammation. We present the case of a 73-year-old woman with synchronous lesions of the pancreas 
and gallbladder initially considered as two primary localized cancers and treated with curative intent. At 
relapse, targeted next generation sequencing (NGS), performed in search of potential therapeutic targets, 
uncovered the fact that the two lesions appeared to be clonally related. This case illustrates the problem 
of synchronous lesions of the pancreas and gallbladder. New pathologic assessments with comparative 
molecular analysis of mutational profiles may be helpful in this context.
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Introduction
Patients with synchronous tumors are a well-recognized 
and frequently encountered problem in clinical oncology. 
Currently there is no consensus on the definition of 
synchronous cancer. Among the proposed definitions 
are: “two or more histologically distinct simultaneously 
detected malignancies” or “two or more histologically 
distinct malignancies arising in the same site, following 
each other in sequence by less than 2 months” (1). In such 
cases it is important to establish whether the tumors have 
arisen independently of each other or whether one lesion is 
the metastasis of the other, since the prognosis and clinical 
management may differ in each situation.
Independent primary pancreato-biliary tumors are rare 
and most are thought to be associated with pancreatobiliary 
reflux (2). Only seven cases have been reported with 
simultaneous cancers of gallbladder and pancreas 
(Table 1). Pancreatic metastases are very uncommon and 
are only found in a minority (3–12%) of patients with 
widespread metastatic disease at autopsy. They account 
for only 2–5% of all pancreatic malignancies and the most 
common primaries encountered include kidney, melanoma 
and breast cancer (10).
Gallbladder and extra-hepatic biliary cancer is a relatively 
rare disease with an estimated 12,360 new cases in the United 
States in 2019. Its incidence increases with age and is slightly 
more common in women (11). The liver and the peritoneal 
cavity are common sites of metastases in gallbladder cancer 
(GBC). The lungs and the bones are less commonly involved. 
Unusual sites of metastases such as muscle, brain, kidney and 
uterus have also been reported in GBC (12).
Below we present a case of synchronous lesions of 
the pancreas and gallbladder managed as two separate 
primary tumors. After recurrence with liver metastasis, 
the mutational profiles of these two tumor tissues were 
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compared and suggested that the pancreatic mass was 
possibly a metastasis of the GBC.
Case presentation
A 73-year-old Caucasian woman with a history of 
hypercholesterolemia presented with acute painless 
jaundice. Personal and family history was negative for 
neoplastic diseases. Laboratory results upon admission 
revealed elevated transaminases (ASAT 393 U/L, ALAT 
939 U/L), and icteric cholestasis (GGT 633 U/L, bilirubin 
64.9 umol/L). The complete blood count, creatinine and 
electrolytes were normal. A Computed tomography (CT) 
of the abdomen with contrast was performed showing 
dilated bile ducts due to the presence of a mass in the head 
of the pancreas. Moreover, signs of acute cholecystitis 
with thickened gallbladder wall and multiple gallstones 
were described but no distant metastatic lesions (Figure 1). 
Endoscopic retrograde cholangiopancreatography (ERCP) 
showed a stenosis (length of 13 mm) at the lower third of 
major biliary tract and a stent was placed.
Fine needle aspiration cytology (FNAC) of the pancreatic 
mass confirmed the existence of a ductal adenocarcinoma 
(PDAC). PET/CT scan was performed revealing a 
moderate degree of 18-fluorodeoxyglucose (FDG) uptake in 
the pancreas head (SUVbw max.: 10.9 and at the wall of the 
gallbladder (SUVbw max.: 11.2), interpreted as of possible 
infectious etiology with no other suspicious foci (Figure 2). 
The Ca 19-9 level was normal.
Therefore, clinical staging was stage III (T4N0M0) and 
the patient underwent cephalic pancreato-duodenectomy 
with resection of the gallbladder and bilio-enteric 
anastomosis at the level of convergence (Whipple). No 
frozen sections were performed intraoperatively and the 
gallbladder wall thickening was attributed to cholecystitis 
due to obstruction from the pancreatic head carcinoma 
and possibly from cholelithiasis. Surprisingly, pathological 
examination revealed the presence of two different tumors: 
a moderately differentiated ductal adenocarcinoma of the 
pancreas [pT2 pN1 (3/14)] with lymphovascular invasion 
and perineural infiltration as well as positive margins at the 
mesenteric vein, associated with pancreatic intraepithelial 





Ueda et al. 1992 (3) Male 58 Thai Synchronous  
(GBC, PC, BDC)
Diffuse Total pancreatectomy and 
extended cholecystectomy
No information
Minami et al. 2008 (4) Female 50 Japanese Metachronous  
(GBC then PC)
Tail Cholecystectomy then 
spleno-pancreatectomy + 
partial gastrectomy and left 
adrenalectomy
Still alive after  
6.5 years
Lahmar et al. 2010 (5) Female 68 Tunisian Metachronous  
(GBC then PC)
Head Extended cholecystectomy 
with adjuvant chemotherapy 
(cisplatin/5 FU) then 
pancreatoduodenectomy
Still alive after  
1 year
Sato et al. 2003 (6) Man 74 Japanese Synchronous  
(GBC, CBDC, PC)
? Pancreatoduodenectomy Died of recurrence 
after 1 year
Rungsakulkij et al. 
2014 (7)
Female 46 Thai Synchronous  
(GBC, PC)
Head Pancreatoduodenectomy + 




Still alive after  
10 months
Agarwal et al. 2013 (8) Female 35 Indian Synchronous  
(GBC, PC)
Head Cholecystectomy Died 25 days after 
surgery
Mori et al. 2017 (9) Female 72 Japanese Synchronous  
(GBC, PC)
Head Pancreatoduodenectomy + 
cholecystectomy
Died 8 months after 
surgery
GBC, gallbladder cancer; PC, pancreatic cancer. 
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neoplasia of grade 1 in intralobular pancreatic ducts and 
a poorly differentiated adenocarcinoma of the gallbladder 
classified pT3 pN1 (3/5) V1 L1 Pn1 R0, associated with 
high grade biliary intraepithelial neoplasia (BilIN3). 
Adjuvant chemotherapy with Gemcitabine for six months 
was given with excellent clinical tolerance.
Unfortunately, six months after the end of the adjuvant 
therapy, a follow up CT showed a single liver metastasis in 
segment V, confirmed by MRI and by biopsy. The CA 19-9 
serum level was normal. After multidisciplinary discussion, 
a first line palliative chemotherapy with the FOLFOX 
regimen was started. Five months later the patient had 
disease progression with appearance of retroperitoneal 
lymph node and lung metastases. In this context, and in the 
absence of standard second line or clinical trial options, we 
performed a next generation sequencing (NGS) analysis 
(customized NGS panel covering 218 hotspot regions 
of 52 genes from panel Ion Torrent) on the tumors of 
the gallbladder and the pancreas, in order to search for 
potential therapeutic targets (Figure 3). We also assessed 
HER2 status by immunohistochemistry (IHC) and FISH in 
the three disease localizations for which tissue was available 
(gallbladder, pancreas and liver).
NGS analyses revealed a common TP53 gene mutation 
(c.742C>T/p.R248W in exon 7, OncoKB: Loss of function, 
likely oncogenic) in the gallbladder and pancreatic tumors, 
with an additional PTEN gene mutation restricted to the 
gallbladder lesion (c.395G>A/p.G132D in exon 5, OncoKB: 
no available functional data but statistically significant 
hotspot and is predicted to be oncogenic). Of note, no 
KRAS mutation was identified (Table 2). HER2 status was 
heterogeneously positive in the gallbladder lesion, with 
an amplified component and another region characterized 
by an equivocal result both by IHC and by FISH. In the 
pancreatic tumor HER2 status was equivocal (by IHC 
and FISH), while the hepatic lesion showed a low-grade 
amplification.
Altogether, these data suggested the existence of a clonal 
relationship between the three lesions. Although the precise 
chronology of events could not be established, we favoured 
the hypothesis that the starting point was a gallbladder 
adenocarcinoma (developed in association with high-grade 
biliary intraepithelial neoplasia), characterized by a genetic 
heterogeneity and a divergent evolution of two different 
subclones: one subclone metastasized to the pancreas, the 
other subclone acquired a HER2 gene amplification (found 
A B C
Figure 1 CT images. (A) Coronal cut: pancreatic mass with double duct sign. (B) Axial cut: Wirsung dilation due to a pancreatic mass. (C) 
ERCP demonstrating a classic “double duct” sign. CT, computed tomography; ERCP, endoscopic retrograde cholangiopancreatography. 
Figure 2 18-FDG PET/ CT scan at the level of GB and pancreatic head before surgery.
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in a component of the gallbladder tumor and to a lesser 
extent in the liver metastasis).
Based on these results, we added trastuzumab (anti-
HER2 antibody) to our backbone second line palliative 
chemotherapy (FOLFIRI), with stable disease for 5 months. 
At the disease progression, we treated the patient with 
the combination of trastuzumab/lapatinib (tyrosine kinase 
inhibitor of EGFR and HER2), as well as with paclitaxel/
trastuzumab. Unfortunately, the patient presented with 
brain symptomatic metastasis treated by surgery followed 
by rapid deterioration of her general condition and died 
four weeks later. The NGS analysis of the brain metastasis 
revealed the common TP53 gene mutation present in the 
other locations as well as an EGFR mutation and a strong 
amplification of the HER2.
Discussion
Only a few cases have been reported in the literature of 
concomitant or metachronous pancreatic carcinoma and 
GBC (Table 1). Interestingly all cases but one were from 
Asia and all cases but one for which information is available 
involved the head of the pancreas. In our case the clinical 
challenge was to make the distinction between pancreatico-
biliary primary tumor with related metastatic lesions or 
two independent primary pancreatico-biliary tumors 
since both of them have similar histologic appearance and 
immunophenotypes, mainly regarding the expression of 
the same cytokeratin panel. An additional challenge in our 
case stemmed from the presence of the pancreatic mass, 
biliary dilatation and gallstones that diverted suspicion 
from a gallbladder carcinoma till the pathology of the 
cholecystectomy was available. GBC has nonspecific 
symptoms including pain, anorexia, nausea, or vomiting 
often leading to a diagnosis only at the time of surgical 
exploration for abdominal symptoms attributable to acute 
or chronic cholecystitis. In fact an incidental finding of 
GBD in cholecystectomies has been reported in 0.2% 
to 2.5% in various series. Ultrasonography (US) for 
diagnosis of GBC has limited sensitivity and additional 
imaging [CT or magnetic resonance imaging (MRI)] is 
needed for patients who have concerning findings on US 
(mass protruding into the lumen, loss of interface between 
gallbladder and liver, gallbladder polyps ≥10 mm, direct 
liver infiltration, thickened gallbladder wall that is not 
explained by cholecystitis).
Recent technological advances such as NGS may be 
helpful for the determination of whether there is a clonal 
relationship between different tumor tissues from the same 
patient.
Gallbladder Pancreas Liver metastasis
Figure 3 Pathology images. Hematoxylin and eosin stained sections, 100× original magnification.
Table 2 NGS panel findings
Gene Gallbladder lesion Pancreatic lesion Brain metastasis Liver metastasis
TP53 c.742C>T c.742C>T c.742C>T Not done
KRAS No mutation No mutation No mutation Not done
ERBB2 Amplification >19copies/cell 
(equivocal in some areas)
Equivocal Amplification >55copies/cell Amplification
PTEN c.395G>A No mutation No mutation Not done
Other EGFR, GNAS amplification CDH1 deletion Not done
NGS, next generation sequencing.
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GBC have a spectrum of mutations including more 
commonly TP53, KRAS, PIK3CA (13), but these overlap 
with pancreatic carcinomas. However frequencies of these 
mutations defer.
TP53 is a tumor suppressor gene and its mutations 
are found in a majority of human malignancies. TP53 
mutations were seen in 73.9% of pancreatic cancer patients 
and in 47% of GBC (14,15).
KRAS mutations in biliary tract cancer have been 
found commonly in the setting of anomalous junction of 
pancreatic and biliary ducts. KRAS mutations have been 
implicated in >95% of PDAC and are considered as an early 
or initiating event for PDAC carcinogenesis (16). Mutations 
most commonly occur at codons 12 (54–74%), 13 (3–5%), 
and 61 (3–5%). On the other hand, a low incidence of KRAS 
mutations has been described in most studies of GBC in 
western countries (0–10%), although the data from Japanese 
studies are more variable (incidence 0–59%) (15,17). In this 
context, the absence of KRAS mutation in the analysis of 
the pancreatic lesion, although it is not conclusive, points 
against a pancreatic primary.
PTEN is a major tumor suppressor and inhibitor of the 
PI3K-Akt kinase pathway but mutations are uncommon 
in pancreatic ductal adenocarcinoma where it regulates 
an NF-kappaB-centered cytokine network (18). PTEN 
mutations are also rare in GBC. In the recent analysis of 
Ali and al of 141 cases of GBC, it has been showed that 
PTEN mutations occur in 4.8% of patients and all of 
them where observed in exon 9. The presence of mutation 
exon 5 is common in other cancers and a possible allelic 
variation of PTEN gene in different ethnic groups has been 
observed (19).
HER2 amplification occurred in as many as 14% 
of the advanced GBC cases. Interestingly, it had been 
shown that recurrent mutations in the ErbB pathway are 
linked with worse outcome. Clinical data suggest that a 
HER2-targeting strategy may be beneficial in this group of 
patients (20,21).
Given the above observations, and given the genetic 
heterogeneity and divergent evolution derived from the 
NGS genomic studies, we favour the hypothesis that the 
starting point was the gallbladder. This primary tumor 
acquired amplifications of HER2 in some areas which 
metastasized to the liver and brain while other clones 
without HER2 amplification travelled across the biliary tree 
and developed invasive metastasis in the pancreas.
The prognosis of metastatic gallbladder is poor, with 
a median survival of less than 12 months (22). Few case 
reports have reported interesting outcomes after surgery for 
selected oligometastatic patients (3-9). Surgical resection 
can be performed safely in selected patients with isolated 
metastases to the para-aortic lymph node or isolated liver 
metastasis, achieving long-term survival as well as good 
palliation (23). In our case, the patient benefited from an 
HER2-targeting strategy with a long survival of 3 years.
In summary, the pancreas represents an uncommon 
but clinically significant site of metastasis in gallbladder 
adenocarcinoma when simultaneous lesions are found. NGS 
can provide valuable information in the workup of these 
cases, when available. However, given the high cost of NGS 
at this time, a cost-benefit analysis should be considered 
before routine use. In our case, use of a targeted NGS 
panel led to use of targeted treatments and resulting in 
meaningful prolongation of patient’s survival. In addition, 
the case illustrates the usefulness of PET scanning in 
evaluation of hepato-biliary tumors. However, one has to 
be careful before ascribing increased up-take to infection 
or inflammation. Finally, in cases where there is a solitary 
metastasis of the gallbladder to the pancreas, as in our case, 
and if radical simultaneous resection is feasible, it should be 
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